Keywords: AstraZeneca, Caprelsa, Vandetanib, Thyroid cancer, CHMP opinion, EMA

AstraZeneca’s thyroid cancer drug Caprelsa gets positive CHMP opinion

Article | 18 November 2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that its Marketing Authorization Application for Caprelsa (vandetanib) has received a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

AstraZeneca

Go to company listing

Related Drugs

Caprelsa

vandetanib

Go to drug listing